Most Read AstraZeneca shares rise as UK coronavirus vaccine trial resumes Sept 14 (Reuters) – Shares of AstraZeneca rose 1% to 8,516 pence on Monday after the British drugmaker received the go-ahead from safety watchdogs over the weekend to resume clinical trials for its COVID-19 vaccine candidate in the United Kingdom.The resumption of the trials for the vaccine, one of the most advanced in development and regarded by governments and financial markets as one of the best bets to tackle the health crisis in the months ahead, buoyed stock markets around the world.The late-stage trials of the vaccine were suspended last week after an illness in a study participant, casting doubts on an early rollout and sending the London-listed company’s shares lower.Global trials of the vaccine had also been paused following the UK suspension.
Brazil has approved restarting the trials and the Serum Institute of India is awaiting permission from the Drugs Controller General of India.Cambridge-based AstraZeneca’s shares had risen about 11% this year up to their Friday close, giving the pharmaceutical giant a market capitalisation of 111 billion pounds ($142 billion).($1 = 0.7803 pounds) (Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty) 2020-09-14 09:04:42
© 2020 Thomson Reuters.
All rights reserved.Reuters content is the intellectual property of Thomson Reuters or its third party content providers.Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon.”Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.Most read today What is RSS? » Risk Disclosure: Sharenet will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals.Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Currency trading on margin involves high risk, and is not suitable for all investors.Trading or investing in crypto currencies carries with it potential risks.Prices of crypto currencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.Crypto currencies are not suitable for all investors.Before deciding to trade foreign exchange or any other financial instrument or crypto currencies you should carefully consider your investment objectives, level of experience, and risk appetite.Sharenet would like to remind you that the data contained in this website is not necessarily real-time nor accurate.All CFDs (stocks, indexes, futures), Forex and crypto currencies prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes.
Therefore Sharenet doesn’t bear any responsibility for any trading losses you might incur as a result of using this data.Sharenet may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics.The calculation/derivation may include underlying JSE data.
Sharenet Group of Companies are authorised financial services providers.Sharenet Securities FSP#: 28430 | Sharenet Wealth FSP#: 41688 © 2020 SHARENET (PTY) Ltd, Cape Town, South Africa.
